Bekinda is an irritable bowel syndrome with diarrhea treatment.
Here’s what you should know.
1. Researchers are conducting a randomized, double-blind, placebo-controlled phase II study evaluating Bekinda’s safety and efficacy in 127 patients with IBS-D.
2. Researchers enrolled patients in a randomized 60 to 40 ratio to receive either Bekinda or a placebo treatment, once-daily for eight weeks. Researchers are measuring stool consistency as compared to baseline.
3. RedHill expects results in the third quarter of fiscal year 2017. RedHill is also conducting a similar study with Bekinda 24 mg. The company expects results for that study in the second quarter of fiscal year 2017 second quarter.
More articles on gastroenterology:
Gastro Health acquires Gastroenterology Consultants: 4 key notes
GI leader to know: Dr. Adedayo Mokuolu of Desert Gastroenterology Associates
Tenapanor provides ‘compelling’ symptom relief in phase IIb trial: 3 insights
